(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Find the Insider facts of Viable Advertising: Building a Positive Brand Picture- Is an $85 apple pie worth it? Our Thanksgiving taste test says … maybe.
- All that You Want to Be familiar with Dental Inserts Centers
- Top Breakfast Food: What's Your Morning Joy?
- Everyday Seasonal Positions That Compensate Fairly in the US
- Step by step instructions to Pick the Right Web-based Degree Program
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Are your hormones imbalanced? Doctors explain how to know if you need testing
- Becoming the best at Systems administration: Individual and Expert Tips
